10 Best Inexpensive Stocks to Buy According to Hedge Funds

8. Bristol-Myers Squibb Company (NYSE:BMY)

Forward P/E Ratio as of September 8: 7.75

Number of Hedge Fund Holders: 67

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC).

The data, consistent with a prior Phase 2 trial in China, showed encouraging anti-tumor activity and a manageable safety profile. The results were presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona. The interim analysis, with a data cut-off date of August 7, included 43 patients with previously untreated ES-SCLC. The safety profile was manageable, with a discontinuation rate of 14%.

Pumitamig is a bispecific antibody that combines 2 mechanisms: PD-L1 checkpoint inhibition and the neutralization of VEGF-A. This dual action is intended to restore the immune system’s ability to fight cancer and cut off the tumor’s blood supply. The positive results from the Phase 2 trial support the ongoing global pivotal Phase 3 trial, ROSETTA LUNG-01, which is comparing pumitamig plus chemotherapy against standard-of-care treatment in first-line ES-SCLC. In 2025, pumitamig received Orphan Drug designation from the US FDA for the treatment of small-cell lung cancer.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BioNTech (NASDAQ:BNTX) is a biotechnology company that develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.